Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma

被引：0
作者：
Supaporn Numpadit
Chiaki Ito
Takaaki Nakaya
Katsuro Hagiwara
机构：
[1] Rakuno Gakuen University,School of Veterinary Medicine
[2] Kyoto Prefectural University of Medicine,Department of Infectious Disease
来源：
Medical Oncology | / 40卷
关键词：
Malignant melanoma (MM); rNDV; GFP; cIFNγ; Oncolytic virotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Malignant melanoma is aggressive cancer with a high rate of local invasiveness and metastasis. Currently, the treatment options for patients with advanced-stage and metastatic oral melanoma are limited. A promising treatment option is oncolytic viral therapy. This study aimed to evaluate novel therapies for malignant melanoma using a canine model. Oral melanoma, which frequently occurs in dogs is used as a model for human melanoma, was isolated and cultured and used for the evaluation of the tumor lytic effect induced by viral infection. We constructed a recombinant Newcastle disease virus (rNDV) that promotes the extracellular release of IFNγ from the virus-infected melanoma. The expression of oncolytic and apoptosis-related genes, the immune response by lymphocytes, and IFNγ expression were evaluated in virus-infected melanoma cells. The results showed that the rate of rNDV infection varied according to the isolated melanoma cells and the oncolytic effect differed between melanoma cells owing to the infectivity of the virus. The oncolytic effect tended to be greater for the IFNγ-expressing virus than for the GFP-expressing prototype virus. Additionally, lymphocytes co-cultured with the virus showed induced expression of Th1 cytokines. Therefore, recombinant NDV expressing IFNγ is expected to induce cellular immunity and oncolytic activity. This oncolytic treatment shows promise as a therapeutic approach for melanoma treatment once evaluated using clinical samples from humans.
引用
收藏
相关论文
共 241 条
  • [1] Fujisawa Y(2019)Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma Cancer Med 8 2146-2156
  • [2] Yoshikawa S(2007)Melanoma Study Group of the Mayo Clinic Cancer Center, Malignant melanoma in the 21st Century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis Mayo Clin Proc 82 364-380
  • [3] Minagawa A(2018)Oral melanoma and other pigmentations: when to biopsy? J Eur Acad Dermatol Venereol 32 209-214
  • [4] Takenouchi T(2009)Primary melanoma of the oral cavity: ten cases and review of 177 cases from literature Med Oral Patol Oral Cir Bucal 14 E265-E271
  • [5] Yokota K(2014)Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management J Dermatol Case Rep 8 60-66
  • [6] Uchi H(2021)Current Melanoma Treatments: Where Do We Stand? Cancers 13 221-982
  • [7] Noma N(2020)From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review Cancers (Basel) 12 3057-92
  • [8] Nakamura Y(2020)Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients Cancers (Basel) 12 2359-1236
  • [9] Asai J(2020)Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors Immune Netw 20 949-571
  • [10] Kato J(2021)Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners Cancer Metastasis Rev 40 83-1034
12345678910